AstraZenecom's new crown vaccine interim results: Show a strong immune response

July 20, AstraZenecom announced that the interim results of the ongoing Phase I/II COV001 trial, led by Oxford University, showed that the recombinant adenovirus vaccine AZD1222 was toned among all assessed subjects and produced a strong immune response to the new coronavirus.
said post-Phase II/III trials of the vaccine are currently being conducted in the UK, Brazil and South Africa and will begin in the US. The trial will determine how the vaccine can prevent neo-coronavirus-related diseases and measure safety and immune response between age groups and doses.
as early as April 30 this year, AstraZeneta announced that it was working with Oxford University to develop a new crown vaccine. The vaccine, named ChaAdOx1 nCoV-19 and later known as AZD1222, is a recombinant adenovirus vaccine, according to AstraZenecom's global website.
AZD1222 was developed by Oxford University and its spin-off company, Vaccitech, using a viral vector based on a weak version of the adenovirus, which contains the genetic material of SARS-CoV-2 spike protein. After vaccination, a surface prickly protein is produced, which, if later infected, triggers the immune system to attack COVID-19.
COV001 is a single-blind randomized controlled trial of I/II designed to determine the safety, immunogenicity and efficacy of the new crown candidate vaccine AZD1222 in 1,077 healthy adults in five trial centres in the UK.
assalicon, results published in The Lancet confirm that a single dose of AZD1222 can increase the number of new coronavirus prickly protein antibodies by four times in 95 percent of participants within a month of injection. In all participants, the T-cell response was induced, peaking on the 14th day and maintaining for two months after injection.
91 percent of the participants and 100 percent of the participants who received the second dose after one month of vaccination saw the mesoactive action against the new coronavirus. The levels of the mesoth antibody in participants treated with one or two doses were similar to among patients with new coronary pneumonia (COVID-19) during the recovery period. Strong correlations were observed in neutral experiments.
In addition, early safety responses confirmed that transient local and systemic reactions in the AZD1222 group were common and comparable to previous trials and other adenovirus vector vaccines, including temporary injection site pain and pain, mild to moderate headache, fatigue, chills, fever, systemic fatigue and muscle pain. AZD1222 did not report serious adverse events, and the use of the painkiller acetaminophen reduced the reaction and occurred less frequently after the second drug.
Lead researcher at Oxford University's Oxford Vaccine Trials and co-author of the trial, Professor Andrew Pollard, said: "Our mid-stage I/II data for the coronavirus vaccine suggest that the vaccine has not caused any unexpected reactions and is safe similar to previous vaccines of this type. The immune response observed after vaccination is consistent with our expected anti-neoviral protection, although we must continue our rigorous clinical trial program to confirm this. Among the participants who were vaccinated with two doses, we saw the strongest immune response, suggesting that this might be a good strategy for vaccination. Mene Pangalos, executive vice president of biopharmaceutical research and development at
AstraZenecon, said: "We are encouraged by the interim I/II data, which show that AZD1222 produces rapid antibodies and T-cell responses to the new coronavirus. While more needs to be done, today's data increase our confidence that vaccines will work and enable us to continue our plans for mass-produced vaccines for widespread and equitable use worldwide. At
, AstraZene will continue to live up to its commitment to broad and equitable access to vaccines if late-stage clinical trials prove successful. To date, more than 2 billion doses of vaccines have been agreed with the Alliance for Innovation in Epidemiology Prevention (CEPI), the Vaccine Alliance Gavi, the Indian Serum Institute (SII) and the Alliance for Inclusive Vaccines (IVA).
astrain said it did not expect the news to affect the company's financial guidance for 2020, as the cost of developing the vaccine was expected to be offset by funding from government and international organizations.